Developing novel therapeutics for rare genetic conditions

Therachon is a global biotechnology company focused on developing treatments for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon, headquartered in Basel, Switzerland, is a spin-off of an Inserm Unit based in Nice, France.

Latest News

Therachon secures $35 million financing

“This financing validates the work we have been doing at Inserm for the last six years,” said Elvire Gouze, PhD, a senior researcher at Inserm and the University of Nice Sophia Antipolis and Therachon’s founder and scientific advisor. “We have discovered a novel protein therapy that has restored normal skeletal growth and reduced co-morbidities in … Read more